Mengis Capital Management Inc. Acquires Shares of 970 Thermo Fisher Scientific Inc. $TMO

Key Points

• Mengis Capital Management Inc. recently acquired 970 shares of Thermo Fisher Scientific Inc., valued at approximately $393,000, in the second quarter.
• Several institutional investors, including Revolve Wealth Partners and Root Financial Partners, have increased their stakes in Thermo Fisher, reflecting ongoing confidence in the company's performance.
• The company's stock has a current market cap of $201.99 billion and reported earnings of $5.36 per share last quarter, surpassing analysts' expectations.

Mengis Capital Management Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 970 shares of the medical research company's stock, valued at approximately $393,000.

Several other institutional investors also recently added to or reduced their stakes in TMO. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Root Financial Partners LLC raised its position in shares of Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after buying an additional 24 shares in the last quarter. Rossmore Private Capital raised its position in shares of Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock valued at $2,315,000 after buying an additional 24 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock valued at $326,000 after buying an additional 24 shares in the last quarter. Finally, Somerville Kurt F raised its position in shares of Thermo Fisher Scientific by 1.6% during the 2nd quarter. Somerville Kurt F now owns 1,605 shares of the medical research company's stock valued at $651,000 after buying an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last 90 days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $534.92 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm's 50 day moving average price is $487.44 and its 200-day moving average price is $448.31. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a market cap of $201.99 billion, a PE ratio of 30.94, a P/E/G ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TMO. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Evercore ISI increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $593.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.